Oxazolidinones are potent inhibitors of bacterial protein biosynthesis. Previous studies have demonstrated that this new class of antimicrobial agent blocks translation by inhibiting initiation complex formation, while post-initiation translation by polysomes and poly(U)-dependent translation is not a target for these compounds. We found that oxazolidinones inhibit translation of natural mRNA templates but have no significant effect on poly(A)-dependent translation. Here we show that various oxazolidinones inhibit ribosomal peptidyltransferase activity in the simple reaction of 70 S ribosomes using initiator-tRNA or N-protected CCA-Phe as a P-site substrate and puromycin as an A-site substrate. Steadystate kinetic analysis shows that oxazolidinones display a competitive inhibition pattern with respect to both the P-site and A-site substrates. This is consistent with a rapid equilibrium, ordered mechanism of the peptidyltransferase reaction, wherein binding of the A-site substrate can occur only after complex formation between peptidyltransferase and the P-site substrate. We propose that oxazolidinones inhibit bacterial protein biosynthesis by interfering with the binding of initiator fMet-tRNA i Met to the ribosomal peptidyltransferase Psite, which is vacant only prior to the formation of the first peptide bond.
In recent years, the discovery and development of structurally novel antibiotics with distinct mechanisms of action have become particularly important because of the emerging resistance of pathogenic bacteria to all classes of existing drugs. Oxazolidinones, which were first discovered at E. I. DuPont de Nemours and Co. in 1983 (1) , are the only new class of synthetic antimicrobial agent introduced into clinical practice within the last 30 years. Although these compounds block protein biosynthesis (2), they inhibit neither translation by polysomes (3) nor the poly(U)-dependent reaction (4) . However, oxazolidinones do bind preferentially to the 50 S subunit of bacterial ribosomes (5, 6) and inhibit the transcription-translation coupled reaction (4) . These agents do not affect the formation of the 30 S preinitiation complex (6, 7), but they do prevent the formation of the N-formylmethionyl-tRNA⅐ribosome⅐mRNA ternary complex (7) . Except for two contradictory reports of their effect upon peptide bond formation (4, 6) and one of no effect in a termination assay (4), the inhibitory action of oxazolidinones in functional translation assays has not been fully investigated.
The lack of clarity surrounding the mechanism of oxazolidinone action suggested to us that more thorough kinetic studies, at different levels of complexity, might prove illuminating. We used detailed initial velocity kinetics studies to decipher the mechanism of action of these inhibitors. Here we show that oxazolidinones inhibit (a) the translation of natural mRNAs; (b) the puromycin reaction that utilizes 70 S ribosomes, initiator fMet-tRNA i Met , and puromycin; and (c) the fragment reaction, which involves 70 S ribosomes, CCA-Phe-X-biotin and puromycin. Furthermore, we demonstrate that oxazolidinones behave as competitive inhibitors with respect to both the P-site and A-site substrates of ribosomal peptidyltransferase.
EXPERIMENTAL PROCEDURES
Reagents and Materials-Poly(A), poly(U), puromycin, RNase-free DNase, and tRNA i Met were purchased from Sigma. Total tRNA from Escherichia coli MRE 600 and RNA markers I and II were obtained from Roche Molecular Biochemicals. SAM 96 Biotin Capture plates, RiboMAX TM Large Scale RNA Production System-SP6, and pSP luc ϩ plasmid were purchased from Promega. A Sephacryl S-300 column, gradient 4 -15 PhastGels, and DNA PhastGel buffer strips were obtained from Amersham Pharmacia Biotech. Microscint-20 and Microscint-40 were purchased from Packard Bioscience Co. [ 3 H]Puromycin (50 Ci/mmol) was obtained from Moravek Biochemicals (Brea, CA). GraFit software (version 4.03) was obtained from Erithacus Software Limited (Horley, Surrey, U. K.). KaleidaGraph (version 3.5) was from Synergy Software (Reading, PA). The ribotrinucleotide 5Ј-rC-rC-rA-3Ј (CCA) 1 was purchased from Oligos etc. (Wilsonville, OR) and used without purification. 6-[(biotinoyl)amino]hexanoic acid succinimidyl ester (biotin-X-NHS ester) was purchased from Molecular Probes (Eugene, OR). L-Phenylalanine t-butyl ester hydrochloride was obtained from Fluka/Sigma. Sparsomycin was obtained from Drug Synthesis & Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute. DuP 721, XA043 and linezolid (see structures in Scheme 1) were synthesized as described in Refs. 8 -10 at DuPont Pharmaceuticals Company.
Preparation of E. coli 70 S Ribosomes and S-100 Protein ExtractTight couple 70 S ribosomes from E. coli MRE 600 were prepared essentially as described by Spedding (11) with minor modifications. Bacterial cells (50 g) were suspended in buffer A (20 mM HEPES-KOH (pH 7.6 at 0°C), 6 mM MgCl 2 , 30 mM NH 4 Cl, 4 mM 2-mercaptoethanol, 0.1 mM phenylmethylsulfonyl fluoride, and 0.1 mM benzamidine hydrochloride). Cells were broken by grinding with prechilled alumina in buffer A (50 ml) followed by the addition of an equal volume of buffer A supplemented with 2-mercaptoethanol, phenylmethylsulfonyl fluoride, and benzamidine hydrochloride. After incubation with RNase-free DNase (30 min at 0°C), alumina and cell debris were removed by centrifugation at 15,000 and 30,000 ϫ g, respectively. The supernatant fluid was then layered over an equal volume of 1.1 M sucrose in buffer B (buffer A containing 0.5 M NH 4 Cl) and centrifuged at 100,000 ϫ g for 15 h. The upper part of the supernatant fluid was collected and dialyzed against buffer A (4 liters, three times). After washing with Polymix buffer (20 mM HEPES (pH 7.5 at 0°C), 5 mM MgCl 2 , 8 mM putrescine, * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. 4 Cl, 95 mM KCl, 1 mM dithioerythritol or 3 mM 2-mercaptoethanol), the ribosomal pellet was resuspended in buffer C (Polymix buffer containing 0.5 M NH 4 Cl) and loaded onto a Sephacryl S-300 column preequilibrated with buffer C. Size fractionation was performed by elution with buffer C (400 ml) at a flow rate of 0.5 ml/min. Fractions containing 70 S ribosomes were pooled, concentrated by centrifugation at 100,000 ϫ g overnight, and redissolved in buffer A. Because analysis of the gel filtration fractions did not show any significant contamination with dissociated 30 S and 50 S subunits, the gel filtration step was omitted in further preparations. The procedure yielded ϳ50 nmol tight-couple 70 S ribosomes.
Preparation of Initiator fMet-tRNA i Met -Synthesis of f-[ 35 S]MettRNA f Met was performed as described (12) using purified tRNA f Met and S-100 extract as a source of formyltransferase, and methionyl-tRNA synthetase. The concentration of tRNA i Met was estimated via specific radioactivity of the final preparation as well as by evaluation of the maximum radioactivity incorporation in the puromycin reaction at saturating concentrations of ribosomes and puromycin. Depending on the quality of acceptor tRNA, a typical preparation had specific radioactivity of 0.02-0.03 Ci/pmol.
Preparation of N-(6-((Biotinoyl)amino)hexanoyl)-L-phenylalanine tButyl Ester (Biotin-X-Phe-O-tBu) (Scheme 2)
-A solution of 6-((biotinoyl)amino)hexanoic acid succinimidyl ester (250 mg, 0.55 mmol), Lphenylalanine t-butyl ester hydrochloride (142 mg, 0.55 mmol), and triethylamine (84 l, 0.60 mmol) in dry dimethylformamide (5.5 ml) was stirred overnight at room temperature. The reaction was poured into water and extracted with 5% methanol in dichloromethane. The organic layer was washed twice with water, dried over magnesium sulfate, and concentrated. The residue was recrystallized from a boiling mixture of ethyl acetate and hexane to afford 250 mg of the title compound as a white solid. MS (ESϩ) m/e ϭ 583 (M ϩ Na). 1 Preparation of N- 
biotin-X-Phe-O-tBu (247 mg, 0.44 mmol) in trifluoroacetic acid (0.44 ml) was stirred overnight, concentrated to dryness, and coevaporated with ethanol. The residue was dissolved in methanol (0.44 ml), and 1 M tetra-n-butylammonium hydroxide in methanol (0.48 ml, 0.48 mmol) was added. After concentrating the reaction mixture to dryness, the residue was coevaporated with dry toluene and dissolved in dry dimethylformamide (about 2 ml). Chloroacetonitrile (31 l, 0.49 mmol) was added, and the reaction was stirred overnight. The reaction was added to water and extracted three times with dichloromethane. The combined organic layers were dried over magnesium sulfate, concentrated to dryness, and used without further purification. 1 Preparation of CCA-Phe-X-Biotin (Scheme 2)-Oligonucleotides were handled in diethyl pyrocarbonate-treated sterile water. The procedure of Ellman et al. (13) was modified. The CCA trinucleotide was converted to the tetra-n-butylammonium salt by passing an aqueous solution of trinucleotide through a 5-g column of Bio-Rex 70 resin (prepared from the sodium form by washing sequentially with 70% ethanol-water, water, 0.1 N aqueous sodium hydroxide, water, 0.1 N aqueous hydrochloric acid, water until neutral, 0.1 N tetra-n-butylammonium hydroxide, and water until neutral). To the lyophilized CCA (504 A 260 , 18 mol) was added an 0.25 M solution of biotin-X-Phe-O-CH 2 CN in dry N,N-dimethylformamide (0.36 ml of 0.25 M stock), and the reaction was stirred at room temperature for 1 h. HPLC of an aliquot quenched into water showed the presence of one major lipophilic product (which reverted to starting trinucleotide upon standing at room temperature). This product was isolated by preparative HPLC on a 1 ϫ 25-cm C18 reverse phase HPLC column with a 5-60% gradient of acetonitrile in 50 mM aqueous ammonium acetate at pH 4. Preparation of luc ϩ mRNA-Messenger RNA of firefly luciferase was synthesized using RiboMAX TM Large Scale RNA Production System-SP6 and pSP luc ϩ vector carrying the lucϩ allele according to the instructions provided by Promega. The resulting mRNA was purified by G-25 gel filtration chromatography, phenol extraction, and ethanol precipitation. The size and purity of luciferase mRNA were assessed using gradient polyacrylamide gel electrophoresis under denaturing conditions (4 -15% PhastGels with DNA PhastGel buffer strips) using RNA markers I and II.
mRNA-dependent Translation-All mRNA-dependent translation reactions were carried out at room temperature in a 50-l total assay volume. Translation of luc ϩ mRNA (0.14 mg/ml) was performed in buffer D (20 mM HEPES (pH 7.9 at 0°C), 54 mM NH 4 Cl, 12 mM MgCl 2 , 0.05 mM spermine, 2 mM spermidine, 1.6 mM ATP, 0.05 mM GTP, and 5 mM phosphoenol pyruvate) containing 0.4 mg/ml total tRNA, 0.28 mg/ml S-100 extract, 0.03 mg/ml pyruvate kinase, and 0.28 M 70 S ribosomes from E. coli MRE 600 in the presence of 50 M amino acids with 20 M [ 14 C]leucine (300 mCi/mmol) as a source of label. Reactions were stopped with equal volume of 10% trichloroacetic acid containing 1% bovine serum albumin (5:1 v/v) followed by precipitation and washing procedure essentially as described (11) . Initial rates of the reaction in the presence of different concentrations of inhibitors were determined from stopped time point assays (20 min). The progress in these reactions was linear for at least 45-60 min, which assured linearity. KaleidaGraph software was used both for plotting and linear regression analysis of all data.
Poly(N)-dependent Translation-The Poly(N)-dependent translation reactions were carried out at room temperature in a 50-l total assay volume. Translation of poly(U) template was done as described in Ref. 14. Translation of poly(A) (at a 1 mg/ml concentration) was performed in buffer E (20 mM HEPES-KOH (pH 7.6 at 0°C), 30 mM NH 4 Cl, 4 mM 2-mercaptoethanol, 9 mM MgCl 2 , 0.05 mM spermine, 2 mM spermidine, 1.6 mM ATP, 0.05 mM GTP, and 5 mM phosphoenol pyruvate) in the presence of 50 M amino acids, 10 M [ 14 C]lysine (300 mCi/mmol), 0.4 mg/ml total tRNA, 0.3 mg/ml S-100 extract, 0.03 mg/ml pyruvate kinase, and 0.28 M 70 S ribosomes. Radiolabeled peptide product was detected as described above for mRNA-dependent translation.
Puromycin Reaction-Peptidyltransferase activity using puromycin as a substrate was assayed essentially as described by Monro (15) . The reactions were carried out on ice and contained the following components: 36.7 mM Tris-HCl (pH 7. Fragment Reaction-The fragment peptidyltransferase reactions were performed at room temperature and contained the following com-SCHEME (16) in which the A-site substrate can bind only to the preformed P-substrate⅐ribosome complex. It was also shown that under physiological conditions, the formation of the first peptide bond occurs via a rapid equilibrium mechanism (17, 18) .
However, the puromycin reaction is MeOH-dependent, and thus the sequence of substrates binding might differ from the physiological situation. Assuming rapid equilibrium conditions (where for a given substrate, K m Х K d ), an ordered bisubstrate reaction can be described as in Reaction 1.
Correspondingly, the rapid equilibrium random Bi Bi reaction can be depicted as in Reaction 2.
REACTION 2
Reciprocal plots at various concentrations of a competitive inhibitor of the first substrate, the P-site substrate in our study, should intersect on the 1/v axis above the horizontal axis when either A or B is varied (19) . Competitive reciprocal patterns for both substrates would distinguish the P-site inhibitor from the inhibitor competitive with the second, A-site, substrate. For the latter, reciprocal plots would show an uncompetitive pattern with respect to the P-substrate and a competitive pattern with puromycin as the varied substrate (19) . Inhibition patterns for competitive inhibitors of both sites for the rapid equilibrium and steady-state cases have been analyzed, and the results are summarized in Table I .
Inhibitor studies versus the P-site substrate were performed at fixed concentrations of puromycin Oxazolidinones Are Competitive Inhibitors of Ribosomal P-siteV max , and K i ) and by F test estimates. The apparent inhibition constant (K i app ) was defined as a slope replot intercept for the varied substrate.
RESULTS
Oxazolidinones are known to inhibit the protein biosynthesis pathway (2) as well as the coupled transcription-translation reaction (4). To refine our understanding of the mechanism of oxazolidinone action, we examined their inhibitory activity in translation systems of various levels of complexity, ranging from mRNA-dependent translation to simple peptide bond formation.
Effect of Oxazolidinones upon mRNA Translation-The luc ϩ mRNA translation assay was used to test whether oxazolidinones inhibit translation uncoupled from transcription. Inhibition curves for DuP 721, XA043, linezolid, and chloramphenicol (a non-oxazolidinone control) are shown in Fig. 1 . The data show that three oxazolidinones inhibit this reaction to different extents. Whereas one of the early oxazolidinones, DuP 721, shows little effect, the second generation inhibitor, XA043, is even more potent than linezolid. The observed incomplete inhibition may result from the presence of endogenous RNA templates in the reaction mix derived from the E. coli extracts. In addition, because the S-100 protein extract is the source of both translation factors and aminoacyl-tRNA synthetases, the level of control over many components in this reaction (including substrates) is restricted.
Effect of Oxazolidinones upon Poly(A) Translation-
The poly(A)-dependent translation reaction was used to test elongation step components as possible targets for oxazolidinones. Poly(A), rather than poly(U), was chosen as the template because poly(U) translation is insensitive to well known elongation step inhibitors such as chloramphenicol and erythromycin (20, 21) . The poly(A) reaction, however, is sensitive to various translation elongation inhibitors including fusidic acid, kirromycin, tobramycin, sparsomycin, tetracycline, erythromycin, and chloramphenicol. None of the three oxazolidinones tested was inhibitory in this reaction (Fig. 2) .
Effect of Oxazolidinones upon Peptide Bond Formation-To distinguish between initiation factors and the peptidyltransferase site as possible targets, oxazolidinones were tested in puromycin reaction, an assay specific for peptide bond formation. In this reaction, 70 S ribosomes catalyze peptide bond formation using initiator fMet-tRNA f Met and puromycin as Pand A-site substrates, respectively, in buffer containing 30% MeOH to overcome the requirement for translation factors and mRNA. As seen in Fig. 3 , the three oxazolidinones tested inhibit peptide bond formation in this assay.
Effect of Oxazolidinones upon Fragment Reaction-The fragment puromycin reaction is the simplest reaction catalyzed by ribosomal peptidyltransferase. Truncated N-protected aminoacylated oligonucleotides with a length of 3 or longer can serve as an alternative substrate to the complete initiator fMettRNA i Met in the puromycin reaction (22, 23) . With this in mind, a partial P-site substrate that mimics the isoacceptor end of tRNA molecule aminoacylated with N-protected phenylalanine (CCA-Phe-X-biotin) was synthesized. This molecule was accepted as a substrate in the peptidyltransferase reaction, and known inhibitors blocked the reaction. As seen in Fig. 4 , oxazolidinones inhibit the fragment reaction with truncated P-site substrate.
Analysis of the Mode of Inhibition of Puromycin Reaction with Oxazolidinones-To probe further the mechanism of action of oxazolidinones, initial velocity studies as a function of inhibitor and substrate concentrations were conducted using the puromycin reaction. To select a valid substrate concentration range, apparent K m app values for both substrates were determined. Values of ϳ0.01 M for initiator fMet-tRNA i Met and ϳ20 M for puromycin were obtained.
Fixing the puromycin (A-site substrate analog) concentration at saturating levels (150 M), the initial velocity of reactions catalyzed by 70 S ribosomes in the presence of varying concentrations of initiator fMet-tRNA i Met (P-site substrate) at different concentrations of inhibitor was measured. The results of inhibition using XA043 are shown in Fig. 5A . The pattern of lines in the reciprocal plot suggests that XA043 behaves as a competitive inhibitor with respect to the P-site substrate. The best fit of these data to various models of inhibition using nonlinear regression analysis by the Marquart-Levenburg algorithm confirmed this finding. A similar competitive pattern has been observed for linezolid (see The puromycin reaction was used to examine the effect of inhibitors on the A-site. Oxazolidinones behave as competitive inhibitors of the A-site substrate as well (Fig. 6, A and B) . Replots of the reciprocal plot slopes and nonlinear least square fit yielded a K i app value for puromycin of 15 Ϯ 3 M with K i app values of 10 Ϯ 2 M for XA043 and 29 Ϯ 4 M for linezolid. Thus, in any case oxazolidinones are competitive inhibitors with respect to initiator tRNA at the P-site and may also be competitive inhibitors of the A-site, if peptidyltransferase MeOH reaction has a random mechanism of action.
DISCUSSION
Despite vigorous research efforts, the molecular target of the oxazolidinone class of antibiotics has remained elusive (1-7). Binding studies (5, 6) implicate the 50 S subunit of the ribosome, the site of peptide bond formation. The inability of oxazolidinones to inhibit polysomal translation has focused the search to targets related to the initiation stage of translation (2) . Inhibition of the initiation complex formation among initiator tRNA, mRNA, and ribosome (7) further supported the idea of initiation as a target step for these antimicrobials. Although Burghardt et al. (6) efforts by several groups to devise a mechanism of action for oxazolidinones which would be supported by the above studies.
Rather than continue to use binding assays, we turned to functional translation assays to approach the problem. By looking for inhibition in assays containing different components of the translation process, we were able to eliminate, step by step, the components that are not inhibited in physiologically relevant reactions.
Oxazolidinones inhibit protein biosynthesis as well as coupled transcription-translation reactions (2, 4) . To confine the study of mechanism to the translation step, oxazolidinones were first tested in an mRNA-dependent translation assay to rule out inhibition of transcription. The template for the mRNA-dependent translation assay was synthesized, purified, and characterized in a separate in vitro SP6 transcription reaction. Oxazolidinones do have an inhibitory effect on mRNA-dependent translation (Fig. 1) . This observation narrowed possible targets for oxazolidinones to formylase, aminoacyl-tRNA synthetases, the ribosome, and initiation, elongation, and termination factors.
Poly(A)-dependent translation was next used to filter the list of possible targets. Although poly(U) is commonly used as a model template, assays utilizing it in place of mRNA are not sensitive to several well known inhibitors of peptide bond formation, such as chloramphenicol and erythromycin (20, 21) . This phenomenon could be responsible for the absence of inhibition of poly(U)-dependent translation by oxazolidinones reported earlier (4). However, none of the oxazolidinones tested inhibited either poly(A) (Fig. 2) or poly(U)-dependent translation (data not shown). Because the termination step has already been ruled out as a target (7), and aminoacyl-tRNA synthetases and elongation factors have been eliminated by both polysomal experiments (2, 4) and results on poly(A) and poly(U) translation, only steps leading to the synthesis of the first peptide bond remained as possible targets for oxazolidinones.
As mentioned before, inhibition of peptide bond formation had been reported previously (6) , but because of controversy over the poly(U) assay and other negative results (4), this finding has not been pursued further. To separate the effects on initiation factors from those on peptide bond formation itself, we studied the inhibition of the puromycin reaction in 30% MeOH by oxazolidinones. This reaction requires only the 70 S ribosome and its substrates, without the need for initiation factors.
Our results clearly indicate that oxazolidinones inhibit formation of the first peptide bond (Figs. 3 and 4) and in a manner that is competitive with respect to the P-site and possibly to the A-site, substrates (Fig. 5, A and B) . Referring to Table I , these results are consistent with the following possibilities: (a) a rapid equilibrium, ordered puromycin reaction mechanism with oxazolidinones acting as competitive inhibitors for the P-site only; (b) a rapid equilibrium, random puromycin reaction mechanism with oxazolidinones acting as geometric analogs (defined as inhibitors that bind a free enzyme in a manner as to exclude both substrates from binding).
Because it is known that the peptidyltransferase P-site must be occupied for the A-site substrate to be able to form a complex with peptidyltransferase (16), the ordered mechanism seems likely under physiological conditions. Nonetheless, because binding of puromycin to the peptidyltransferase center of the ribosome was reported to be independent of the P-substrate (24) under the MeOH reaction conditions, it cannot be excluded that oxazolidinones bind to an unliganded form(s) of the ribosome in a way that precludes binding of both substrates. For example, oxazolidinones may bind predominantly to the P-site on the 50 S subunit (under physiological conditions, before its assembly with the 30 S preinitiation complex) but hinder the A-site only sterically, hence appearing as a competitive inhibitor of the acceptor site under MeOH fragment reaction conditions. This mode of binding can explain why under physiological conditions oxazolidinones do not inhibit the A-site if the donor site is preoccupied with initiator or peptidyl-tRNA. In either case, oxazolidinones are competitive inhibitors of the P-site substrate binding.
That inhibition of the peptidyltransferase P-site is the mechanism of oxazolidinone action not only is consistent with much of data on oxazolidinones but also resolves the major controversy. Because the P-site of peptidyltransferase is vacant only during the initiation stage of translation, interference of oxazolidinones with initiator tRNA binding can occur only prior to the first bond formation. After that, the P-site is occupied continuously by peptidyl-tRNA during elongation. This model explains why the elongation step is not inhibited and why the MeOH puromycin reaction is. Thus, all of the evidence collected to date supports inhibition of the P-site as the primary mechanism of action for these novel compounds.
Our observation that oxazolidinones are competitive inhibi- tors of initiator tRNA may explain why initiation complex formation was not inhibited in earlier studies (26) . Because initiation factors 1, 2, and 3 are present in low amounts intracellularly (0.1-0.2 M) (29, 30) and are probably limiting factors in the translation process, the physiological relevance of competitive binding experiments, which are usually performed at a high concentration of these components, is questionable. Similarly, one might argue that inappropriate concentration of reagents and/or a different order of addition of the reaction components could be responsible for the absence or presence of inhibition of the template-dependent puromycin reaction observed in other studies (5, 6) .
Recently, two new reports have discussed the mechanism of inhibition of oxazolidinones (25, 26) . Genetic evidence that oxazolidinone-resistant mutations are associated exclusively with domain V of 23 S RNA (peptidyltransferase active site) (25) is in a good agreement with the peptidyltransferase inhibition data presented here as well as with our mutagenesis results (27, 28) . 2 Inhibition of the fragment reaction, which utilizes only the CCA fragment of peptidyl-tRNA and puromycin as substrates, places the oxazolidinone binding site in close proximity to the 50 S P-site of the peptidyltransferase active center. Cross-linking to the E-site (26) of an analog containing an azido group positioned distally from the oxazolidinone core itself further supports our finding of the peptidyltransferase center as a target for oxazolidinones because it has been shown that the E-site is in close proximity to the P-site (31, 32) . Based on inhibition analysis and mutagenesis results, it is likely that the binding site for oxazolidinones overlaps with the P-site of the ribosomal peptidyltransferase. This mode of binding is consistent with our proposal: oxazolidinones inhibit formation of the first peptide bond.
